Skip to main content
. 2016 Sep 14;7(41):67333–67346. doi: 10.18632/oncotarget.12024

Figure 4. s-Arg-1 is increased in HL.

Figure 4

Concentration of arginase in serum (s-Arg-1) is reported for healthy volunteers and HL patients at diagnosis (panel A). Reduction in s-Arg-1 occurred by first two months of ABVD treatment, deeper at the end of planned treatment (B), except for PET-2 positive (panel C) or non-responder patients (panel D).